iTeos Therapeutics Presents Interim Data at ESMO 2024
iTeos Therapeutics Presents Interim Data at ESMO 2024
iTeos Therapeutics, Inc. (Nasdaq: ITOS) is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. The company has announced that interim data from GALAXIES Lung-201, a Phase 2 platform study sponsored by GSK, focusing on belrestotug + dostarlimab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer (NSCLC), will be showcased through a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.
Late Breaking Oral Presentation Details
The presentation will cover the interim analysis of GALAXIES Lung-201. The abstract, numbered LBA52, will be featured in the Proffered Paper Session: NSCLC Metastatic. This session is scheduled for September at 8:30 am CEST / 2:30 am ET.
About iTeos Therapeutics, Inc.
As a pioneering clinical-stage biopharmaceutical company, iTeos Therapeutics focuses on crafting new immuno-oncology therapeutics. With a deep understanding of tumor immunology and immunosuppressive mechanisms, the company designs innovative product candidates. Their pipeline includes clinical-stage programs that tackle novel immunosuppressive pathways with improved pharmacologic properties aimed at enhancing clinical outcomes. iTeos Therapeutics is headquartered in Watertown, MA, and operates a research center in Gosselies, Belgium.
About Belrestotug
Belrestotug, known as EOS-448 or GSK4428859A, is a potent Fc active human IgG1 monoclonal antibody targeting TIGIT, a significant inhibitor of immune responses against cancer. This innovative therapeutic candidate enhances the antitumor response by engaging with TIGIT and Fc?R, which plays a vital role in immune response regulation. Belrestotug is actively progressing through various indications in collaboration with GSK.
Investor Information
iTeos Therapeutics regularly shares information essential for investors in the 'Investors' section of its website at www.iteostherapeutics.com. Staying updated on iTeos is encouraged for investors and potential investors.
Contact Information
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
Frequently Asked Questions
What is iTeos Therapeutics known for?
iTeos Therapeutics is recognized for developing innovative immuno-oncology therapeutics aimed at improving patient outcomes.
What is the significance of the GALAXIES Lung-201 study?
The GALAXIES Lung-201 study evaluates the efficacy of a combination therapy in treating advanced non-small cell lung cancer, potentially transforming treatment approaches.
When will the interim data be presented?
The interim data will be presented during a late-breaking session at the ESMO Congress in September 2024.
What role does GSK play in the study?
GSK is the development partner sponsoring the GALAXIES Lung-201 study, aiding in the evaluation of the therapeutic combination.
How can investors stay updated on iTeos Therapeutics?
Investors can stay informed via the 'Investors' section on iTeos Therapeutics' official website for the latest developments and important information.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/